{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-057460","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.082965+00:00","generated_at":"2026-05-14T19:51:24.363006+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data","bullets":["Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.","Phase 2b CLOVER WaM: 83.6% ORR, 61.8% MRR, median DoR 17.8 months in r/r WM.","BTKi-exposed: 64.1% MRR, median PFS 15.9 mo; BTKi-refractory: 63.6% MRR, median PFS 14.8 mo.","Nantahala gets board seat; warrants exercisable upon stockholder approval at $2.65.","Proceeds to support Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057460","json":"https://secwatch.observer/filing/0001104659-26-057460.json","markdown":"https://secwatch.observer/filing/0001104659-26-057460.md","text":"https://secwatch.observer/filing/0001104659-26-057460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/tm2613728d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T19:51:24.363006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0dee20f8b95bd671c7b9aded1bed215a2b9f6f63","claim":"Cellectar Biosciences, Inc. entered into Management Purchase Agreement with certain members of the executive management team of the Company (effective 2026-05-04).","evidence_excerpt":"pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain members of the executive management team of the Company"},{"label":"Effective","value":"2026-05-04"}],"fact_type":"material_agreement"},{"claim_id":"2d408d0829d7d099df05d5290a43660955520445","claim":"Cellectar Biosciences, Inc. entered into Investor Purchase Agreement with certain institutional investors (effective 2026-05-04).","evidence_excerpt":"On May 4, 2026, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement with certain institutional investors (the “Investor Purchaser Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Effective","value":"2026-05-04"}],"fact_type":"material_agreement"},{"claim_id":"366d90277a37382908349b617f5af69046a4af22","claim":"Cellectar Biosciences, Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. (effective 2026-05-04).","evidence_excerpt":"on May 4, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Effective","value":"2026-05-04"}],"fact_type":"material_agreement"},{"claim_id":"cc874a5f123b4de3e8704c0aab459806cb8f747f","claim":"Cellectar Biosciences, Inc. entered into Registration Rights Agreement with certain investors (effective 2026-05-04).","evidence_excerpt":"on May 4, 2026, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with certain investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"certain investors"},{"label":"Effective","value":"2026-05-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}